Phase 3 Adjuvant Therapy Clinical Trials
12 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–12 of 12 trials
Recruiting
Phase 3
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
Breast CancerNeoadjuvant TherapySentinel Lymph Node Biopsy
Seoul National University Hospital464 enrolled1 locationNCT06704945
Recruiting
Phase 3
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Breast CancerAdjuvant Therapy
Fudan University1,903 enrolled1 locationNCT07019363
Recruiting
Phase 3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Neoadjuvant TherapyImmunotherapyLocally Advanced Non-Small Cell Lung Cancer+1 more
Sun Yat-sen University497 enrolled1 locationNCT06734702
Recruiting
Phase 3
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant TherapyAdjuvant ChemotherapyGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+3 more
Zuoyi Jiao668 enrolled4 locationsNCT06949033
Recruiting
Phase 3
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
RadiotherapyImmunotherapyLocally Advanced Rectal Cancer (LARC)+2 more
West China Hospital184 enrolled1 locationNCT07020247
Recruiting
Phase 3
Neoadjuvant SNF Precision Therapy Phase III
Neoadjuvant Therapy
Fudan University404 enrolled1 locationNCT06913777
Recruiting
Phase 3
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.1,600 enrolled2 locationsNCT06126640
Recruiting
Phase 3
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant TherapyAdjuvant ChemotherapyGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+3 more
Zuoyi Jiao682 enrolled4 locationsNCT06925243
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 2Phase 3
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant TherapyEsophageal Squamous Cell Carcinoma
Army Medical Center of PLA266 enrolled1 locationNCT06354530
Recruiting
Phase 3
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Neoadjuvant TherapyHead and Neck Squamous Cell CarcinomaPembrolizumab
Beijing Tongren Hospital272 enrolled1 locationNCT06102395
Active
Phase 3
Multicentre international study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer
Colorectal Cancer - Adjuvant Therapy
Australiasia Gastro_Intestinal Trial Group (AGITG)2,152 enrolled1 locationACTRN12606000361505